ENTX
Entera Bio Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$3.00
+1.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | 42.0K | 181.0K | — | 134.0K |
| Cost of Revenue | 15.0K | 42.0K | 172.0K | 56.0K | 165.0K |
| Gross Profit | (15.0K) | — | 9.0K | (56.0K) | (31.0K) |
| Operating Expenses | |||||
| R&D Expense | 8.8M | 6.0M | 4.5M | 4.5M | 5.8M |
| SG&A Expense | 5.6M | 5.5M | 5.1M | 4.4M | 7.3M |
| General & Admin Expense | 5.6M | 5.5M | 5.1M | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 14.4M | 11.5M | 9.6M | 8.9M | 13.0M |
| Cost and Expenses | 14.4M | 11.6M | 9.8M | 8.9M | 13.2M |
| Operating Income (EBIT) | (14.4M) | (11.5M) | (9.6M) | (8.9M) | (13.1M) |
| Non-Operating | |||||
| Interest Income | — | — | 58.0K | 31.0K | 83.0K |
| Interest Expense | 2.7M | — | — | — | — |
| Net Interest Income | (2.7M) | — | 58.0K | 31.0K | 83.0K |
| Other Non-Op Income/Expense | (2.6M) | 90.0K | 58.0K | 80.0K | 134.0K |
| Non-Operating Income (excl Interest) | (116.0K) | (90.0K) | (58.0K) | (80.0K) | (134.0K) |
| EBT (Pre-Tax Income) | (17.0M) | (11.4M) | (9.5M) | (8.9M) | (12.9M) |
| Income Tax Expense | — | — | 14.0K | 29.0K | 137.0K |
| Bottom Line | |||||
| Net Income | (17.0M) | (11.4M) | (9.5M) | (8.9M) | (13.1M) |
| Earnings from Cont. Ops | (17.0M) | (11.4M) | (9.5M) | (8.9M) | (13.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (17.0M) | (11.4M) | (9.5M) | (8.9M) | (13.1M) |
| Per Share | |||||
| Basic EPS | ($0.35) | ($0.25) | ($0.25) | ($0.31) | ($0.45) |
| Diluted EPS | ($0.35) | ($0.25) | ($0.25) | ($0.31) | ($0.45) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 50.5M | 46.2M | 37.7M | 29.0M | 28.8M |
| Diluted Shares Outstanding | 50.5M | 46.2M | 37.7M | 29.0M | 28.8M |
| Profitability Metrics | |||||
| EBITDA | (14.3M) | (11.4M) | (9.5M) | (8.8M) | (12.9M) |
| D&A | 22.0K | 30.0K | 46.0K | 56.0K | 64.0K |
| EBIT | (14.3M) | (11.4M) | (9.5M) | (8.9M) | (12.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026